DEEP SEQUENCING ANALYSES IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH SIMEPREVIR PLUS SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN THE COSMOS STUDY

被引：0
|
作者：
Fevery, B. [1 ]
Thys, K. [1 ]
Van Rossem, E. [1 ]
Verbinnen, T. [1 ]
Picchio, G. [2 ]
Aerssens, J. [1 ]
De Meyer, S. [1 ]
Beumont, M. [1 ]
Kurland, D. [2 ]
Lenz, O. [1 ]
机构：
[1] Janssen Infect Dis BVBA, Beerse, Belgium
[2] Janssen Res & Dev LLC, Titusville, NJ USA
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)30983-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P0780
引用
收藏
页码：S623 / S623
页数：1
相关论文
共 50 条
  • [21] Influence of apolipoprotein E genotype on virologic response in HCV type 1-infected patients treated with PEG-IFNA plus ribavirin
    Weich, V
    Teuber, G
    Sarrazin, C
    Klinker, H
    Buggisch, P
    Schott, E
    Bergk, A
    Witt, H
    Berg, T
    HEPATOLOGY, 2005, 42 (04) : 687A - 687A
  • [22] SOFOSBUVIR plus PEGINTERFERON/RIBAVIRIN FOR 12 WEEKS VS SOFOSBUVIR plus RIBAVIRIN FOR 16 OR 24 WEEKS IN GENOTYPE 3 HCV INFECTED PATIENTS AND TREATMENT-EXPERIENCED CIRRHOTIC PATIENTS WITH GENOTYPE 2 HCV: THE BOSON STUDY
    Foster, G. R.
    Pianko, S.
    Cooper, C.
    Brown, A.
    Forton, D.
    Nahass, R. G.
    George, J.
    Barnes, E.
    Brainard, D. M.
    Massetto, B.
    Lin, M.
    McHutchison, J. G.
    Subramanian, G. M.
    Agarwal, K.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S259 - S260
  • [23] Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients
    Khatri, Amit
    Mensing, Sven
    Podsadecki, Thomas
    Awni, Walid
    Menon, Rajeev
    Dutta, Sandeep
    CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 625 - 635
  • [24] Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
    Lawitz, Eric
    Sulkowski, Mark S.
    Ghalib, Reem
    Rodriguez-Torres, Maribel
    Younossi, Zobair M.
    Corregidor, Ana
    DeJesus, Edwin
    Pearlman, Brian
    Rabinovitz, Mordechai
    Gitlin, Norman
    Lim, Joseph K.
    Pockros, Paul J.
    Scott, John D.
    Fevery, Bart
    Lambrecht, Tom
    Ouwerkerk-Mahadevan, Sivi
    Callewaert, Katleen
    Symonds, William T.
    Picchio, Gaston
    Lindsay, Karen L.
    Beumont, Maria
    Jacobson, Ira M.
    LANCET, 2014, 384 (9956): : 1756 - 1765
  • [25] Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients
    Amit Khatri
    Sven Mensing
    Thomas Podsadecki
    Walid Awni
    Rajeev Menon
    Sandeep Dutta
    Clinical Drug Investigation, 2016, 36 : 625 - 635
  • [26] Management of Hemoglobin Decrease in Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients
    Rustgi, Vinod
    Bernstein, David
    Sepe, Thomas
    King, William
    Diago, Moises
    Andreone, Pietro
    Forton, Daniel
    Reesink, Hendrik
    Ferenci, Peter
    Hu, Yiran
    Enejosa, Jeffrey
    Cohen, Daniel
    Luo, Yan
    Pedrosa, Marcos
    Vierling, John
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S133 - S133
  • [27] Efficacy of Ledipasvir plus Sofosobuvir with or without ribavirin in hepatitis C genotype 1 patients who failed previous treatment with Simeprevir plus Sofosbuvir
    Gonzales, Gabriel R.
    Gonzalez, Stevan A.
    Nazario, Hector E.
    Gautam, Manjushree
    Barnes, Maisha
    Mantry, Parvez S.
    Weinstein, Jeffrey S.
    Ndungu, Milka
    Teachenor, Olga
    Modi, Apurva A.
    HEPATOLOGY, 2015, 62 : 775A - 775A
  • [28] Sofosbuvir plus Peginterferon/Ribavirin for 12 weeks vs. Sofosbuvir plus Ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study
    Pianko, S.
    Cooper, C.
    Brown, A.
    Forton, D.
    Nahass, R.
    George, J.
    Barnes, E.
    Brainard, D.
    Massetto, B.
    Lin, M.
    Mchutchinson, J.
    Subramanian, G. M.
    Agarwal, K.
    Foster, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 90 - 90
  • [29] Safety and Efficacy of Sofosbuvir in Combination with Daclatasvir or Simeprevir With or Without Ribavirin in the Treatment of Chronic HCV Genotype 4-infected Patients: A Real World Experience
    Babatin, Mohamed A.
    Albenmousa, Ali H.
    Alothmani, Hammad S.
    Alghamdi, Abdullah S.
    Bzeizi, Khalid I.
    Aljaroudi, Mandi E.
    Albiladi, Haziz
    Alsahafi, Ashwaq
    Sanai, Faisal M.
    HEPATOLOGY, 2016, 64 : 999A - 1000A
  • [30] Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil
    Aguiar, Bruna Forte
    Campos, Guilherme Rodrigues Fernandes
    Rodrigues, Joao Paulo Vilela
    Marques, Nayara Nathie
    Molina, Barbara Floriano
    Bittar, Cintia
    Souza, Fernanda Fernandes
    Martinelli, Ana de Lourdes Candolo
    Rahal, Paula
    Pereira, Leonardo Regis Leira
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2020, 44 (03) : 329 - 339
12345